CARLSBAD, Calif.--(BUSINESS WIRE)--April 17, 2006--Invitrogen Corporation (Nasdaq:IVGN - News) today announced preliminary results for its first quarter ended March 31, 2006. Revenues for the first quarter increased 12% to $309 million versus the same period last year. Sales were lower than anticipated by approximately 3% due to lower than expected performance in its US Bioproduction and Japan businesses. Revenue performance in Europe, US research, and emerging markets were strong. Pro forma earnings per share for the first quarter of 2006 were slightly higher than anticipated due to improved mix, lower royalty expense and lower share count. The company will provide further detail on financial performance during the previously scheduled conference call on April 27, 2006.
